NASDAQ:ICLR - Icon Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$133.18 -0.24 (-0.18 %)
(As of 01/22/2019 07:47 AM ET)
Previous Close$133.42
Today's Range$131.54 - $134.63
52-Week Range$101.22 - $155.33
Volume310,679 shs
Average Volume264,679 shs
Market Capitalization$7.20 billion
P/E Ratio24.71
Dividend YieldN/A
Beta0.67
ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. The company's clinical development services include product development planning, strategic consulting, study protocol preparation, clinical pharmacology, pharmacokinetic and pharmacodynamic analysis, clinical research center, investigator site, patient recruitment, study monitoring and data collection, case report form preparation, statistical analysis, patient safety and risk-based monitoring, clinical data management, strategic analysis and data operation, regulatory consulting, and medical reporting and pharmacovigilance services. Its clinical development services also comprise interactive response technologies, electronic endpoint adjudication, medical imaging, adaptive trial design and execution, medical device and biosimilar trial, functional, strategic resourcing, sample analyses, safety testing, microbiology, custom flow cytometry, biomarker development, bioanalysis, immunoassay development, patient registries, outcomes research, health economics, market access and commercialization, drug price consulting, and healthcare and scientific communication services, as well as research trials for the U.S. government agencies, electronic transmission of test results, and electronic patient reported outcomes. The company was founded in 1990 and is headquartered in Dublin, Ireland.

Receive ICLR News and Ratings via Email

Sign-up to receive the latest news and ratings for ICLR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ICLR
CUSIPN/A
Phone353-1291-2000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.76 billion
Cash Flow$6.5996 per share
Book Value$22.02 per share

Profitability

Net Income$281.48 million

Miscellaneous

Employees13,250
Market Cap$7.20 billion
OptionableOptionable

Icon (NASDAQ:ICLR) Frequently Asked Questions

What is Icon's stock symbol?

Icon trades on the NASDAQ under the ticker symbol "ICLR."

How were Icon's earnings last quarter?

Icon Plc (NASDAQ:ICLR) posted its quarterly earnings results on Wednesday, October, 24th. The medical research company reported $1.54 earnings per share for the quarter, meeting the consensus estimate of $1.54. The medical research company had revenue of $655.02 million for the quarter, compared to analyst estimates of $654.66 million. Icon had a return on equity of 26.08% and a net margin of 12.88%. View Icon's Earnings History.

When is Icon's next earnings date?

Icon is scheduled to release their next quarterly earnings announcement on Thursday, February 21st 2019. View Earnings Estimates for Icon.

What guidance has Icon issued on next quarter's earnings?

Icon updated its FY19 earnings guidance on Tuesday, January, 8th. The company provided earnings per share guidance of $6.69-6.89 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $6.79. The company issued revenue guidance of $2.74-2.84 billion, compared to the consensus revenue estimate of $2.79 billion.Icon also updated its FY18 guidance to $5.98-6.12 EPS.

What price target have analysts set for ICLR?

9 equities research analysts have issued 12 month target prices for Icon's stock. Their predictions range from $136.00 to $168.00. On average, they anticipate Icon's share price to reach $151.3750 in the next year. This suggests a possible upside of 13.7% from the stock's current price. View Analyst Price Targets for Icon.

What is the consensus analysts' recommendation for Icon?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Icon in the last year. There are currently 1 sell rating, 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Icon.

Has Icon been receiving favorable news coverage?

News articles about ICLR stock have trended very positive on Tuesday, according to InfoTrie Sentiment. The research firm ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Icon earned a media sentiment score of 3.2 on InfoTrie's scale. They also assigned media coverage about the medical research company a news buzz of 4.0 out of 10, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

Who are some of Icon's key competitors?

Who are Icon's key executives?

Icon's management team includes the folowing people:
  • Dr. Steven A. Cutler, CEO & Director (Age 59)
  • Mr. Brendan Brennan, Chief Financial Officer (Age 40)
  • Jonathan Curtain, VP of Corp. Fin. & Investor Relations
  • Mr. Thomas O'Leary, Chief Information Officer
  • Mr. Diarmaid Cunningham, Chief Admin. Officer, Gen. Counsel, Exec. VP & Company Sec. (Age 44)

Who are Icon's major shareholders?

Icon's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Peregrine Capital Management LLC (0.43%), Blackcrane Capital LLC (0.28%), Summit Creek Advisors LLC (0.23%), Boston Advisors LLC (0.14%), LVM Capital Management Ltd. MI (0.11%) and Dorsey Wright & Associates (0.06%).

Which institutional investors are selling Icon stock?

ICLR stock was sold by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Dorsey Wright & Associates, Boston Advisors LLC, Summit Creek Advisors LLC, Bangor Savings Bank, Tealwood Asset Management Inc., Confluence Investment Management LLC and Fulton Bank N.A..

Which institutional investors are buying Icon stock?

ICLR stock was bought by a variety of institutional investors in the last quarter, including Blackcrane Capital LLC, Diversified Trust Co, LVM Capital Management Ltd. MI and Virtu Financial LLC.

How do I buy shares of Icon?

Shares of ICLR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Icon's stock price today?

One share of ICLR stock can currently be purchased for approximately $133.18.

How big of a company is Icon?

Icon has a market capitalization of $7.20 billion and generates $1.76 billion in revenue each year. The medical research company earns $281.48 million in net income (profit) each year or $5.39 on an earnings per share basis. Icon employs 13,250 workers across the globe.

What is Icon's official website?

The official website for Icon is http://www.iconplc.com.

How can I contact Icon?

Icon's mailing address is SOUTH COUNTY BUSINESS PARK LEOPARDSTOWN, DUBLIN L2, 00000. The medical research company can be reached via phone at 353-1291-2000.


MarketBeat Community Rating for Icon (NASDAQ ICLR)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  436 (Vote Outperform)
Underperform Votes:  328 (Vote Underperform)
Total Votes:  764
MarketBeat's community ratings are surveys of what our community members think about Icon and other stocks. Vote "Outperform" if you believe ICLR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ICLR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/22/2019 by MarketBeat.com Staff

Featured Article: Intrinsic Value

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel